Jonathan L Wright1, Philip D Hansten, Janet L Stanford. 1. Department of Urology, University of Washington School of Medicine, Seattle, Washington; Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Abstract
PURPOSE: Digoxin is a commonly used medication for heart failure and cardiac arrhythmias that has recently been suggested as a novel chemotherapeutic agent. Preclinical studies of prostate cancer (PCa) have shown anti-tumor activity with digoxin. We explore the relationship between use of digoxin and PCa risk. METHODS: Data from a population-based case-control study of incident cases aged 35-74 years at PCa diagnosis in 2002-2005 in King County, Washington were available. Controls were identified by random digit dialing and frequency matched by age. Use of digoxin was determined from in-person questionnaires regarding medical and prescription history. The relationship of digoxin use with PCa risk was evaluated with logistic regression. RESULTS: One thousand one cases of PCa and 942 controls were analyzed. The prevalence of digoxin use in controls was 2.7%, and use was positively correlated with age. In multivariate analysis adjusting for age, race, PSA screening, and family history of PCa, digoxin use was associated with a reduction in the odds ratio of PCa (OR 0.58, 95% CI: 0.30-1.10). Among those with ≥3 PSA tests over the preceding 5 years (546 cases, 380 controls), digoxin use was associated with a stronger reduction of PCa risk (OR 0.44, 95% CI: 0.20-0.98). CONCLUSION: These data indicate digoxin use may be associated with a reduction in risk of PCa. Given the potential mechanisms by which digoxin may exert an anti-neoplastic effect and other recent studies showing a negative association between digoxin use and PCa, further research is warranted.
PURPOSE:Digoxin is a commonly used medication for heart failure and cardiac arrhythmias that has recently been suggested as a novel chemotherapeutic agent. Preclinical studies of prostate cancer (PCa) have shown anti-tumor activity with digoxin. We explore the relationship between use of digoxin and PCa risk. METHODS: Data from a population-based case-control study of incident cases aged 35-74 years at PCa diagnosis in 2002-2005 in King County, Washington were available. Controls were identified by random digit dialing and frequency matched by age. Use of digoxin was determined from in-person questionnaires regarding medical and prescription history. The relationship of digoxin use with PCa risk was evaluated with logistic regression. RESULTS: One thousand one cases of PCa and 942 controls were analyzed. The prevalence of digoxin use in controls was 2.7%, and use was positively correlated with age. In multivariate analysis adjusting for age, race, PSA screening, and family history of PCa, digoxin use was associated with a reduction in the odds ratio of PCa (OR 0.58, 95% CI: 0.30-1.10). Among those with ≥3 PSA tests over the preceding 5 years (546 cases, 380 controls), digoxin use was associated with a stronger reduction of PCa risk (OR 0.44, 95% CI: 0.20-0.98). CONCLUSION: These data indicate digoxin use may be associated with a reduction in risk of PCa. Given the potential mechanisms by which digoxin may exert an anti-neoplastic effect and other recent studies showing a negative association between digoxin use and PCa, further research is warranted.
Authors: Elizabeth A Platz; Srinivasan Yegnasubramanian; Jun O Liu; Curtis R Chong; Joong Sup Shim; Stacey A Kenfield; Meir J Stampfer; Walter C Willett; Edward Giovannucci; William G Nelson Journal: Cancer Discov Date: 2011-06 Impact factor: 39.397
Authors: Ilir Agalliu; Claudia A Salinas; Philip D Hansten; Elaine A Ostrander; Janet L Stanford Journal: Am J Epidemiol Date: 2008-06-12 Impact factor: 4.897
Authors: H Lin; S W Wang; S C Tsai; J J Chen; Y C Chiao; C C Lu; W J Huang; G J Wang; C F Chen; P S Wang Journal: Br J Pharmacol Date: 1998-12 Impact factor: 8.739
Authors: Corinna Seliger; Christoph R Meier; Susan S Jick; Martin Uhl; Ulrich Bogdahn; Peter Hau; M F Leitzmann Journal: J Neurooncol Date: 2015-12-31 Impact factor: 4.130
Authors: Markus Wallner; Mounir Khafaga; Ewald Kolesnik; Aris Vafiadis; Gerold Schwantzer; Deborah M Eaton; Pero Curcic; Martin Köstenberger; Igor Knez; Peter P Rainer; Martin Pichler; Burkert Pieske; Dirk Von Lewinski Journal: Oncotarget Date: 2017-07-25